Literature DB >> 24962208

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

N Snelder1, B A Ploeger, O Luttringer, D F Rigel, F Fu, M Beil, D R Stanski, M Danhof.   

Abstract

BACKGROUND AND
PURPOSE: Previously, a systems pharmacology model was developed characterizing drug effects on the interrelationship between mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (TPR). The present investigation aims to (i) extend the previously developed model by parsing CO into heart rate (HR) and stroke volume (SV) and (ii) evaluate if the mechanism of action (MoA) of new compounds can be elucidated using only HR and MAP measurements. EXPERIMENTAL APPROACH: Cardiovascular effects of eight drugs with diverse MoAs (amiloride, amlodipine, atropine, enalapril, fasudil, hydrochlorothiazide, prazosin and propranolol) were characterized in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats following single administrations of a range of doses. Rats were instrumented with ascending aortic flow probes and aortic catheters/radiotransmitters for continuous recording of MAP, HR and CO throughout the experiments. Data were analysed in conjunction with independent information on the time course of the drug concentration following a mechanism-based pharmacokinetic-pharmacodynamic modelling approach. KEY
RESULTS: The extended model, which quantified changes in TPR, HR and SV with negative feedback through MAP, adequately described the cardiovascular effects of the drugs while accounting for circadian variations and handling effects. CONCLUSIONS AND IMPLICATIONS: A systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR was obtained in hypertensive and normotensive rats. This extended model can quantify dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using only HR and MAP measurements. Whether the model can be applied for compounds with a more complex MoA remains to be established.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24962208      PMCID: PMC4253457          DOI: 10.1111/bph.12824

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  The fourth dimension of life: fractal geometry and allometric scaling of organisms.

Authors:  G B West; J H Brown; B J Enquist
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

2.  Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst W Radue
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

Review 3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 4.  Preclinical cardiovascular risk assessment in modern drug development.

Authors:  Brian D Guth
Journal:  Toxicol Sci       Date:  2007-03-09       Impact factor: 4.849

Review 5.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

Review 6.  Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

Authors:  Bart A Ploeger; Piet H van der Graaf; Meindert Danhof
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

7.  Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

Authors:  Edward Perez-Reyes; Amy L Van Deusen; Iuliia Vitko
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

8.  Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.

Authors:  Y Hong; J Dingemanse; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2008-02-20       Impact factor: 6.875

9.  Esterase inhibition attribute of grapefruit juice leading to a new drug interaction.

Authors:  Ping Li; Patrick S Callery; Liang-Shang Gan; Suresh K Balani
Journal:  Drug Metab Dispos       Date:  2007-03-28       Impact factor: 3.922

Review 10.  Lessons from rat models of hypertension: from Goldblatt to genetic engineering.

Authors:  Y M Pinto; M Paul; D Ganten
Journal:  Cardiovasc Res       Date:  1998-07       Impact factor: 10.787

View more
  9 in total

1.  Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.

Authors:  Teresa Collins; Kelly Gray; Michal Bista; Matt Skinner; Christopher Hardy; Haiyun Wang; Jerome T Mettetal; Alexander R Harmer
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

2.  Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities.

Authors:  Raja Venkatasubramanian; Teresa A Collins; Lawrence J Lesko; Jerome T Mettetal; Mirjam N Trame
Journal:  Br J Pharmacol       Date:  2020-06-18       Impact factor: 8.739

3.  Quantitative pharmacokinetic-pharmacodynamic modelling of baclofen-mediated cardiovascular effects using BP and heart rate in rats.

Authors:  Harriet Kamendi; Herbert Barthlow; David Lengel; Marie-Eve Beaudoin; Debra Snow; Jerome T Mettetal; Russell A Bialecki
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

4.  The 24 h pattern of arterial pressure in mice is determined mainly by heart rate-driven variation in cardiac output.

Authors:  Theodore W Kurtz; Heidi L Lujan; Stephen E DiCarlo
Journal:  Physiol Rep       Date:  2014-11-26

5.  Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.

Authors:  Erica L Bradshaw; Mary E Spilker; Richard Zang; Loveleena Bansal; Handan He; Rhys D O Jones; Kha Le; Mark Penney; Edgar Schuck; Brian Topp; Alice Tsai; Christine Xu; Marjoleen J M A Nijsen; Jason R Chan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-25

6.  A quantitative systems pharmacology approach to predict the safe-equivalent dose of doxorubicin in patients with cardiovascular comorbidity.

Authors:  Lan Sang; Yi Yuan; Ying Zhou; Zhengying Zhou; Muhan Jiang; Xiaoquan Liu; Kun Hao; Hua He
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-13

Review 7.  Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs.

Authors:  Hai-Ni Wen; Chen-Yu Wang; Jin-Meng Li; Zheng Jiao
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

8.  A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables.

Authors:  Yu Fu; Hadi Taghvafard; Medhat M Said; Eric I Rossman; Teresa A Collins; Stéphanie Billiald-Desquand; Derek Leishman; Piet H van der Graaf; J G Coen van Hasselt; Nelleke Snelder
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-18

Review 9.  Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment.

Authors:  T A Collins; L Bergenholm; T Abdulla; Jwt Yates; N Evans; M J Chappell; J T Mettetal
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.